Skip to main content
Premium Trial:

Request an Annual Quote

Richard Barker, Thomas Vogel, James Meade, Paul Young


Richard Barker has become executive chairman of the board of directors of New Haven, Conn.-based Molecular Staging. Previously, he was CEO of Chiron Diagnostics and general manager of IBM’s health care solutions business. Before that, he led the pharmaceutical practice in Europe for McKinsey. Barker holds a BA in chemistry and a doctorate in biophysics from the University of Oxford in England.

Thomas Vogel has been appointed to the Board of Directors and the Audit and Compensation Committee of Boston Biomedica, as part of the Board’s expansion. Vogel is the president and CEO of the drug discovery company AdipoGenix. Prior to that, he was CEO and director of Mosaic Technologies and founder of venture capital firm Charlestown Group. At various times previously he has served as president of Fisher Scientific, president of PB Diagnostics, president of Instrumentation Laboratory, and president of Serono Diagnostics. He has also served as divisional vice president and general manager of diagnostic products at Abbott Laboratories. Vogel holds a bachelor’s degree in electrical engineering from the Georgia Institute of Technology and an MBA from Wharton Business School.

James Meade has been named vice president of business development at Avalon Pharmaceuticals, and Paul Young has been promoted to vice president of research at the company. Meade comes to Avalon from Pfizer/Pharmacia, where he worked in global licensing of anti-infective and urology products. He has also worked previously at Bayer, Chiron, and Cetus. Young was most recently senior scientific director of discovery biology at Avalon, and a member of its scientific management committee. Prior to that, he worked as a senior scientist at Human Genome Sciences, and previously, at Bayer and Genentech.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.